Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical ranibizumab after filtration surgery for glaucoma
ISRCTN12125882Phase 3Completed
- Sponsor
- Horten Center
- Start
- Jan 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of ranibizumab in Glaucoma (2 arms), sponsored by Horten Center. Primary endpoint: Intraocular pressure difference. Started Jan 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
Glaucoma
Beyond the preview
Go deeper on ISRCTN12125882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12125882.